about
Biodegradable polymeric microsphere-based vaccines and their applications in infectious diseasesRecent trends in stabilizing protein structure upon encapsulation and release from bioerodible polymers.Effect of polymer chemistry and fabrication method on protein release and stability from polyanhydride microspheresA silica-based pH-sensitive nanomatrix system improves the oral absorption and efficacy of incretin hormone glucagon-like peptide-1Stabilization of tetanus toxoid encapsulated in PLGA microspheres.Encapsulated Brucella ovis Lacking a Putative ATP-Binding Cassette Transporter (ΔabcBA) Protects against Wild Type Brucella ovis in Rams.Issues in oral nanoparticle drug carrier uptake and targeting.Vaccines that facilitate antigen entry into dendritic cells.Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice.Microparticles for oral delivery of vaccines.Cross-linked protein crystals for vaccine deliveryRespiratory nanoparticle-based vaccines and challenges associated with animal models and translationDevelopment and Evaluation of Biodegradable Particles Coloaded With Antigen and the Toll-Like Receptor Agonist, Pentaerythritol Lipid A, as a Cancer Vaccine.Polyanhydride microparticles enhance dendritic cell antigen presentation and activation.Design opportunities for actively targeted nanoparticle vaccines.Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues.Designing polymeric particles for antigen delivery.Radiation sterilization of new drug delivery systems.Current knowledge on biodegradable microspheres in drug delivery.Conjugation, characterization and toxicity of lipophosphoglycan-polyacrylic acid conjugate for vaccination against leishmaniasisSustained cytoplasmic delivery and anti-viral effect of PLGA nanoparticles carrying a nucleic acid-hydrolyzing monoclonal antibody.Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity.Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccineMesoporous silicon microparticles enhance MHC class I cross-antigen presentation by human dendritic cells.Formulation and characterization of immunoreactive tetanus toxoid biodegradable polymer particles.Humoral and cell-mediated immune-responses after administration of a single-shot recombinant hepatitis B surface antigen vaccine formulated with cationic poly(l-lactide) microspheres.Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies.Immunization without needles.Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins.Formulation of maltodextrin entrapped in polycaprolactone microparticles for protein and vaccine delivery: effect of size determining formulation process variables of microparticles on the hydrodynamic diameter of BSA.The effect of in vivo growth on the cellular and extracellular components of the marine bacterial pathogen Photobacterium damsela subsp. piscicida.Chemically modified inulin microparticles serving dual function as a protein antigen delivery vehicle and immunostimulatory adjuvant.Trojan‐Horse‐Like Stimuli‐Responsive Microcapsules.Microencapsulates, Proteins and Lipids/Vesicles
P2860
Q28087409-34C9A7B2-7CBF-454B-A712-FF7965C884FFQ30329989-94D2688C-5F9D-4B03-A4F0-24BBFA6C7465Q30379368-9AECA625-27D7-49D2-8172-E8716B3A9C99Q34426261-457BDF4C-D3C9-46C1-AB41-DF51A9348C4AQ34722666-34C74A8C-7406-49D9-8698-146BC26C1845Q35758615-49E0AEC2-CC37-4103-B56F-0D01FEF2942CQ35809222-D75F6556-AAFA-4790-8976-83622A1B687BQ35915763-13F686CC-25BF-43F3-B067-283D92DE466DQ36161142-C9802916-A116-49F2-B8B2-7ED1C8B58126Q36316809-428EC71D-70C1-4011-A0BB-816D66F53B02Q36420836-92E895B0-D61B-4B53-912E-72A81573EDB0Q36598433-B4DE8A09-DD78-4C4F-B077-0CAE91390632Q36642860-5A556A96-66D4-4CBA-AEDA-CAD4554DC2ECQ37010485-678C9C7E-85C2-4571-88B0-5402F616C84DQ37062606-795F174E-3215-43DB-B459-65836A8231BDQ37098801-A922D5A3-EDBC-48DB-9BE1-B119070FFE1FQ37153923-5F4C7F03-1558-4830-9789-AF87B1D3C709Q37808118-B9AEAE7E-9C1F-48D2-965F-FB0AB55AEB12Q38220822-47E309B2-D698-4CF3-8728-EB739E9323E9Q38357497-991173CB-0A49-4BE8-9696-0F985F7781C6Q39144488-182D5B7F-B9AF-4F8E-88FB-BDB524E204EDQ39433325-27A1C268-F6FF-4631-BA59-0CC2DB5CB870Q39773773-E61C6738-8214-4916-AB12-0BED6D2F0A40Q41512320-0E84E9D6-D7F5-41FC-9127-A6E5E824BC1FQ42250011-C35DB888-7F36-469D-8508-38576246F025Q43411758-6D4CE996-5CA7-4AF9-A0CE-3DA4F70735C8Q45803020-9B53B267-7CD7-4023-BA98-31B58AEC8B3FQ45885233-745D97DC-E1F4-4989-A0DB-0254859B2941Q46308392-4C15D9F3-677C-442B-BE8A-F93368A8E3B7Q46860089-B8B05D5D-864C-48A3-A7BD-0378246CB9EEQ47288698-2B78AAB0-52CA-4291-8469-CAB1E6EDBBBEQ48031455-9EB816C1-5E75-4B52-BC76-08B0F4A22768Q51567300-59520896-7B6E-4F1B-855C-504533BD54FFQ55229980-64C80A65-22E8-4342-87B5-20A288C9792FQ57341176-8EDB0012-4CD2-4C1B-9D7A-E1C8A0D4AE38
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
New advances in microsphere-based single-dose vaccines.
@ast
New advances in microsphere-based single-dose vaccines.
@en
type
label
New advances in microsphere-based single-dose vaccines.
@ast
New advances in microsphere-based single-dose vaccines.
@en
prefLabel
New advances in microsphere-based single-dose vaccines.
@ast
New advances in microsphere-based single-dose vaccines.
@en
P2093
P1476
New advances in microsphere-based single-dose vaccines.
@en
P2093
P304
P356
10.1016/S0169-409X(97)00053-7
P407
P577
1997-10-01T00:00:00Z